Skip to main content

Department of Internal Medicine

Richard Byrd Pollard, M.D. View profile as PDF

Richard Byrd Pollard

Philosophy of Care

My philosophy of care is comprehensive primary care of HIV-infected patients and patients with other infectious diseases.

Clinical Interests

Dr. Pollard’s clinical research includes usage of new antiviral drugs, the care of HIV-infected patients, HIV vaccines as well as clinical immunology. Pollard’s research interests include immunology of viral infections, immune responses to HIV, CMV, HPV, and VZV as well as immunologic non-responders.

Title:

Chief of Infectious Diseases
Professor

Specialty:

Infectious Diseases, Internal Medicine

Department:

Internal Medicine

Division:

Infectious Diseases

Center/Program Affiliation:

Address/Phone:

Lawrence J. Ellison Ambulatory Care Center
Infectious Diseases Clinic
4860 Y St., Suite 0101
Sacramento, CA 95817
Driving Directions
Phone: 916-734-2737

CARES Clinic
1500 21st St.
Sacramento, CA 95811
Driving Directions
Phone: 800-2-UCDAVIS

Additional Phone:

Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Education:

M.D., University of Maryland School of Medicine, Baltimore, Maryland, 1970

Internships:

Ohio State University, Columbus, Ohio, 1970-71

Residency:

Emory University , Atlanta, Georgia, 1973-75

Fellowships:

Stanford University Medical Center, Stanford, California, 1975-78

Board Certifications:

American Board of Internal Medicine, 1975

Professional Memberships:

American Association of Immunologists
American College of Physicians, Fellow
Infectious Diseases Society of America, Fellow
Sigma Xi

Select Honors and Awards:

Best Doctors in America, 2010

Best Doctors in America, 2009

Best Doctors in America, 2007

Select Recent Publications:

Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB; and the AIDS Clinical Trials Group A5192 Team.. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. Journal of Infectious Diseases, 201(11): 1686-1696, 2010.

Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, Yee HFJr, Martin JN, Deeks SG, and Shacklett BL. Immunodominant HIV-Specific CD8 +T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers. Journal of Virology, 84(19): 10354-10365, 2010.

Kalayjian R, Machekano R, Rizk N, Robbins G, Gandhi R, Rodriguez B, Pollard RB, Lederman M, and Landay A. Pre-treatment levels of soluble receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. Journal of Infectious Diseases, 201(12): 1796-1805, 2010.

Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P, and the STARTMRK Investigators. Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. Journal of Acquired Immune Deficiency Syndrome, 2010 Apr 15. [Epub ahead of print], 2010.

Schacker T, Bosch R, Bennett K, Pollard RB, Robbins G, Collier A, Gulick R, Spritzler J, and Mildvan D. Measurement of Naive CD4 Cells Reliably Predicts Potential for Immune Reconstitution in HIV. Journal of Acquired Immune Deficiency Syndrome, 54(1): 59-62, 2010.

Smith K, Zheng L, Bosch R, Margolis D, Tenorio A, Napolitano L, Saag M, Connick E, Lawrence J, Gross B, Francis I, Valdez H, Wang R, Muurahainen N, Stocker V, Pollard RB.. Treatment with recombinant growth hormone is associated with enhanced CD4 lymphocyte reconstitution in HIV-infected subjects with incomplete immune reconstitution on HAART—results of adult AIDS clinical trial group protocol (AACTG) 5174. AIDS Res Human Retrovir, 26(4): 425-432, 2010.

Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JVR, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, O'Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, and Sklar P, for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. The Lancet, 374(9692): 796-806, 2009.

Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Orellana L, Mildvan D, Bazner S, Streeck H, Alter G, Lifson JD, Carrington M, Bosch RJ, Robbins GK, and Altfeld M. Sex differences in the TLR-mediated response of pDCs to HIV-1 are associated with higher immune activation in infected women. Nature Medicine, 15(8): 955-959, 2009.

Gupta SK, Komarow L, Gulick RM, Pollard RB, Robbins GK, Franceschini N, Szczech LA, Koletar SL, and Kalayjian RC. Proteinuria, Creatinine Clearance, and Immune Activation in Antiretroviral-Naive HIV-Infected Subjects. The Journal of Infectious Diseases, 200: 614-618, 2009.

Crawford K, Spritzler J, Kalayjian R, Parsons T, Landay A, Pollard RB, Stocker V, Lederman M, Flexner C.. Age-related changes in pharmacokinetic parameters of the HIV protease inhibitor lopinavir. AIDS Res Human Retrovir, 2009.

Yoshida T, Kobayashi M, Li XD, Pollard RB, and Suzuki F. Inhibitory effect of glycyrrhizin on the neutrophil-dependent increase of R5 HIV replication in cultures of macrophages. Immunology and Cell Biology, 2009(Jun 16): Epub ahead of print, 2009.

To see if Richard Byrd Pollard is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).